



New Artemis Solution Helps Pharmaceutical Firms Drive Greater Investment Efficiency into R&D

NEWPORT BEACH, Calif. Apr 20, 2004 - Unique Approach Integrates Portfolio Management with Budgeting and Program Oversight for Better Pipeline Management Across Matrix Organizations

Artemis International Solutions Corporation (OTCBB:AMSI), specialists in portfolio management, today announced the general availability of the Artemis New Product Development solution for Pharmaceutical R&D. The new enterprise portfolio management system is designed to improve pipeline management processes for pharmaceutical and biotechnology firms.

According to Patrick Ternier, president and CEO of Artemis, effective portfolio management in life sciences research and development has been linked to increased profitability by ensuring that resources and capital are effectively distributed in line with business strategy.

"Pharmaceutical companies are facing increased market pressure that must be translated into more effective R&D planning efforts in order to maintain competitiveness. Portfolio management is a well-understood practice in life sciences, but firms still struggle to reach a desirable level of process maturity. A key part of that challenge is a direct consequence of using fragmented systems resulting in the inability to effectively integrate and drive portfolio decisions down to operational execution," added Ternier. "Artemis has 20 years of experience working with leading pharmaceutical companies and has applied this expertise to design a portfolio management solution to meet these challenges."

Artemis was recently chosen by Actelion Pharmaceuticals Ltd to align and prioritize all products in their portfolio with their business strategy in order to maximize investment returns. "We selected Artemis because of their demonstrated experiences in pharmaceutical companies and the accelerated implementation we will get from their New Product Development solution for Pharmaceutical R&D," explained Miriam Halperin-Wernli, head of Business & Science Affairs for Actelion. "We will be supported in proactively managing our entire portfolio of candidates with timely and accurate cost, schedule, risk, and benefit information that was previously distributed across multiple systems. This will help us establish consistency and an improved process, thereby systematizing, simplifying and speeding up decision cycles."

Artemis' New Product Development solution is developed on the company's enterprise portfolio, project and resource management platform, Artemis 7. It consists of pre-configured software, field-tested process templates and standard reports that have been specifically designed for rapid implementation and return on investment in pharmaceutical and biotechnology firms. The Artemis solution for Pharmaceutical R&D is immediately available.

Another early adopter of the Artemis New Product Development solution is Japan-based Kirin Pharmaceutical.